Gilead HIV prospect escapes FDA hold after glass compatibility glitch triggered regulatory setbacks

Gilead Sciences received the all-clear to pick up studies of its investigational HIV med lenacapavir. Still, the long-acting injectable has yet to fully recover from the sting of its recent glass compatibility snafu.